Swiss pharma giant Novartis (NOVN: VX) has announced the beginning of SURPASS, the first head-to-head clinical trial comparing Cosentyx (secukinumab) to a proposed biosimilar version of Humira (adalimumab) in ankylosing spondylitis (AS).
The SURPASS and EXCEED studies are part of a larger rheumatology program for Cosentyx, with the latter being a head-to-head clinical trial comparing it to Humira (adalimumab) in psoriatic arthritis (PsA), which is already recruiting and is also the first study of its kind.
These data add to the evidence to underline the benefit of different biologic pathways"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze